Invasive Validation of Antares, a New Algorithm to Calculate Central Blood Pressure from Oscillometric Upper Arm Pulse Waves by Dörr, Marcus et al.
Journal of
Clinical Medicine
Article
Invasive Validation of Antares, a New Algorithm to
Calculate Central Blood Pressure from Oscillometric
Upper Arm Pulse Waves
Marcus Dörr 1,2 , Stefan Richter 3, Siegfried Eckert 4, Marc-Alexander Ohlow 3,
Fabian Hammer 1, Astrid Hummel 1, Vivien Dornberger 1, Elisabeth Genzel 1
and Johannes Baulmann 5,6,*
1 Department of Internal Medicine B, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße,
D-17475 Greifswald, Germany
2 German Centre for Cardiovascular Research (DZHK), Partner Site Greifswald, D-17475 Greifswald, Germany
3 Zentralklinik Bad Berka GmbH, Herzzentrum, Department of Cardiology, Robert-Koch-Allee 9,
D-99437 Bad Berka, Germany
4 Klinik für Allgemeine und Interventionelle Kardiologie/Angiologie, Universitätsklinik der Ruhr-Universität
Bochum, Georgstraße 11, D-32545 Bad Oeynhausen, Germany
5 EPC—European Prevention Center, Luise-Rainer-Straße 6-10, D-40235 Düsseldorf, Germany
6 Department of Medical Psychology and Psychotherapy, Medical University of Graz, Auenbruggerplatz 2/8,
A-8036 Graz, Austria
* Correspondence: jbaulmann@yahoo.com
Received: 20 June 2019; Accepted: 18 July 2019; Published: 22 July 2019


Abstract: Background: Antares is an algorithm for pulse wave analysis (PWA) by oscillometric
blood pressure (BP) monitors in order to estimate central (aortic) blood pressure (cBP). Antares
aims to enable brachial cuff-based BP monitors to be type II-devices, determining absolute cBP
values independently of potential peripheral BP inaccuracies. The present study is an invasive
validation of the Antares algorithm in the custo screen 400. Methods: We followed entirely the
2017 ARTERY protocol for validation of non-invasive cBP devices, the 2013 American National
Standards Institute, Inc./Association for the Advancement of Medical Instrumentation/International
Organization for Standardization (ANSI/AAMI/ISO) 81060-2 and 2018 AAMI/European Society of
Hypertension (ESH)/ISO validation standard protocols. In total, 191 patients undergoing cardiac
catheterization were included, of which 145 patients entered analysis. Invasive cBP recordings were
compared to simultaneous non-invasive cBP estimations using the Antares algorithm, integrated
into an oscillometric BP monitor. Results: Mean difference between invasive and non-invasively
estimated systolic cBP was 0.71 mmHg with standard deviation of 5.95 mmHg, fulfilling highest
validation criteria. Conclusion: Antares is the first algorithm for estimation of cBP that entirely fulfills
the 2017 ARTERY and AAMI/ESH/ISO validation protocols. The Antares algorithm turns the custo
screen 400 BP monitor into a type II-device. Integration of Antares into commercially available BP
monitors could make it possible to measure PWA parameters in virtually every practice in future.
Keywords: validation; invasive; central blood pressure; pulse wave analysis; antares
1. Introduction
Central blood pressure (cBP) is not the same as peripheral blood pressure (pBP) [1]. Basically, in a
young, healthy arterial system cBP is low and pBP much higher [1]. When an individual is getting
older, cBP rises and may reach the same level or probably even higher cBP levels than pBP [2]. Several
studies have shown that cBP is more strongly related to hypertension-related organ damage and
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outcome than pBP [3–5]. According to the current European Society of Hypertension/European Society
of Cardiology (ESH/ESC) hypertension guidelines, measurement of cBP has practical consequences
for the treatment of young patients with isolated systolic hypertension [6]. For these individuals, no
medication is necessary if cBP is low. Thus, a potentially huge overtreatment can be avoided. A conditio
sine qua non should be that cBP is estimated accurately.
For the first time, in 2017 a worldwide consensus paper under the leadership of the ARTERY
society was published as a task force consensus statement on protocol standardization for the validation
of non-invasive central pressure devices [7]. A main issue was that the reference standard against
which the device accuracy of central BP estimations is gauged should be intra-arterial (invasive)
catheter in the ascending aorta because “currently there are no non-invasive alternatives”. At the same
time, procedures were defined for (a) the proper performance of the invasive pressure recordings and
the technical requirements, (b) non-invasive central BP device measurement standards, (c) sample
characteristics, and (d) statistical requirements.
The existing devices were categorized as type I or type II devices. Type I means that an estimate of
central BP relative to the measured brachial BP is given in order to concentrate on a relatively accurate
pressure difference between central and peripheral sites. Type II means that these devices estimate
the intra-arterial central BP, what could be understood as the “true” central BP, despite the known
inaccuracy of peripheral BP measurements compared to invasive measurements [8].
The ANSI/AAMI/ISO 81060-2:2013 (American National Standards Institute, Inc. and Association
for the Advancement of Medical Instrumentation) was developed by the International Organization for
Standardization (ISO)/TC 121/SC 3, the International Electrotechnical Commission (IEC)/SC 62D Joint
Working Group (JWG) 7 on non-invasive BP monitoring equipment and the AAMI Sphygmomanometer
Committee. The objective of the standard is to provide minimum labeling, performance, and safety
requirements for the clinical validation of medical electrical equipment used for estimation of the
arterial blood pressure by utilizing a cuff. Most, but not all, of the ANSI/AAMI/ISO 81060-2:2013
recommendations are included in the ARTERY Society task force consensus statement on protocol
standardization for validation of non-invasive central BP devices [9]. 2018 a statement was published
that presents the key aspects of a validation procedure, which were agreed by the AAMI, ESH and
ISO representatives as the basis for a single universal validation protocol [10]. Because in the 2018
statements there are no rules for invasive reference measurements, we did not stop referring to the 2013
ANSI/AAMI/ISO protocol with integrated criteria for hemodynamic stability of invasive measurements
and finally followed both protocols.
Antares is an algorithm for calculating central blood pressure values, which can be integrated into
an oscillometric device at the upper arm. Antares aims to enable an oscillometric BP monitor to act
as a type II-device, thereby providing “true” invasive central BP values. Antares was developed by
Redwave Medical GmbH, Jena, Germany.
The study aims is to invasively validate the central blood pressure calculation of the Antares
algorithm according to the ARTERY validation protocol as well as the 2013 ANSI/AAMI/ISO 81060-2
and the 2018 AAMI/ESH/ISO standard using an oscillometric BP monitor at the upper arm.
2. Material and Methods
We followed entirely the 2017 ARTERY society task force consensus statement on protocol
standardization for the validation of non-invasive central blood pressure devices, the 2013
ANSI/AAMI/ISO 81060-2 and the 2018 AAMI/ESH/ISO standard.
Table 1: Patient characteristics. Blood pressure (BP) range (systolic, diastolic and mean
peripheral and invasive blood pressures), body mass index (BMI), systolic blood pressure (SBP),
mean arterial pressure (MAP), diastolic blood pressure (DBP), percutaneous coronary intervention
(PCI). The non-invasive brachial measurements presented in Table 1 are those recorded at the time of
the angiogram.
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Table 1. Patient characteristics.
Mean Min Max Standard Deviation
Number of included patients 145
Male Sex 65.5%
Age (years) 69.2 26 99 11.6
Height (cm) 171.7 115.0 195.0 10.0
Weight (kg) 83.8 34.0 129.0 17.3
Heart rate (1/min) 69.0 36.3 111.1 12.2
BMI (kg/m2) 28.4 16.6 64.3 4.6
Non-invasive brachial SBP (mmHg) 149.6 89.0 217.0 22.9
Non-invasive brachial MAP (mmHg) 107.4 64.0 151.0 16.6
Non-invasive brachial DBP (mmHg) 85.1 58.0 139.0 12.1
Invasive central SBP (mmHg) 145.1 83.4 225.7 24.0
Invasive central MAP (mmHg) 101.5 62.7 139.5 14.8
Invasive central DBP (mmHg) 72.1 45.5 106.7 12.2
No of patients with coronary artery disease 74 (51%)
No of patients with diabetes 43 (30%)
No of patients with hypertension 103 (71%)
No of patients undergoing PCI 64 (44%)
No of patients on antihypertensive medication 46 (32%)
In total, 191 patients undergoing cardiac catheterization for clinical reasons were included in the
study. According to the criteria of the 2013 AAMI protocol, 14 patients were excluded due to high
variation of invasive BP readings (five patients with standard deviation (SD) in invasive systolic BP
(SBP) >10 mmHg, three patients with SD in invasive mean arterial pressure (MAP) >6 mmHg and six
patients with SD in invasive diastolic BP (DBP) >6 mmHg). Also, 22 patients were excluded due to
severe arrhythmia during the measurements. In one study center, the first 10 measurements had to
be excluded due to a systemic error in zeroing. This resulted in 145 patients being available for the
analysis. All patients who entered the analysis were Caucasians. 107 patients were within a heart rate
of 60–100/min (73.8%).
Table 2 shows the invasive blood pressure values and their distribution according to suggested
blood pressure ranges.
Table 2. Invasive blood pressures and their distribution according to ranges stated in ARTERY validation
protocol and others. Central systolic blood pressure (cSBP), central diastolic blood pressure (cDBP).
Number % of Goal ARTERY Goal
Number of included patients 145 171% 85
cSBP < = 100 3 2.1% 5%
cSBP > 100 < 140 58 40.0%
cSBP > = 140 46 31.7% 20%
cSBP > = 160 38 26.2% 5%
cDBP < = 60 23 15.9% 5%
cDBP > 60 < 85 105 72.4%
cDBP > = 85 15 10.3% 20%
cDBP > = 100 2 1.4% 5%
Study centers: The measurements were performed in three German study centers: Greifswald,
Bad Oeynhausen, and Bad Berka (for details please see the affiliations of 1, 3, and 4).
Most patients were included in Bad Berka (63 patients), followed by Bad Oeynhausen (50 patients)
and Greifswald (32 patients). In all cases, the invasive recording was performed simultaneously to
the non-invasive recording. Out of the 145 patients included in the analysis, 100 cardiac catheters
were performed radially, and 45 were done femorally. The study was conducted in compliance
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with the Declaration of Helsinki. Ethics approval was obtained from the local ethics committees.
All participants gave their informed consent for inclusion before they participated in the study.
Study setting: All measurements were performed in the cardiac catheterization laboratory,
with constant temperature, without excessive ambient noise from monitoring devices. The invasive
and non-invasive measurements were performed at the end of each cardiac catheter examination
and were completely simultaneous. Thus, the patient was adapted to the environment and without
disturbing influences. Data acquisition was done in a period of undisturbed rest, free from acute
hemodynamic interventions, free from acute medication changes and without talking.
Non-invasive central BP device measurement: All non-invasive measurements were performed with
the custo screen 400 device (custo med GmbH, Ottobrunn, Germany), with the integrated Antares
algorithm to calculate central BP on a connected laptop. The familiarization with the equipment
took only a few minutes in each study center because it is the process of a normal blood pressure
measurement. The oscillometric device in its original version is built for 24 h-ambulatory blood pressure
monitoring. The custo screen 400 is validated for peripheral blood pressure measurement according
to ESH-IP 2010 [11]. Cuff size was chosen according to the directives given by the manufacturer
after measurement of the circumference of the upper arm (small 20–24 cm, medium 24–32 cm, large
32–40 cm). The cuff was placed at the left arm, except for two patients (1%) in which the right upper
arm was used. After placing the cuff at the upper arm, a first non-invasive measurement was performed
before the cardiac catheterization in order to test the functioning of the device and to familiarize the
patient with the measurement procedure. This measurement was not included in any calculations.
The second measurement was done simultaneously with the invasive measurement on the opposite
arm. In 99% of the cases invasive radial access was on the right site and the cuff for non-invasive
recordings was placed on the left arm. It was started exactly after the recording of the catheter in the
aorta ascendens was started. Time points of start and end of the non-invasive measurements were
harmonized with the invasive measurement by setting time stamps and marks to definitely be sure of
simultaneous recordings. When severe arrhythmia occurred during the non-invasive and simultaneous
invasive measurement, a second recording was performed. If the second recording was disturbed
by severe arrhythmia again, these recordings were not included in the analysis. After removing the
unacceptable invasive measurements (please see below), all non-invasive measurements could be
analyzed without having to discard a single measurement.
The Antares software version 2.0, developed by Redwave Medical GmbH, Jena, Germany, was
applied in the oscillometric device. Acquisition of the oscillometric pulse waves took place during
the deflation of the cuff. Cuff deflation speed was 4 mmHg/s with a linear deflation via a regulated
valve. Redwave Medical is patent holder for pulse wave analysis (PWA) in pulse waves that are
recorded during inflation and deflation of a cuff (patent no DE 10 2017 117 337 B4). Generally speaking,
it means that the pulse waves generated during a normal oscillometric BP measurement procedure
can be taken for PWA with no need for altering the standard BP pump operation. The recorded
pulse waves were analyzed for non-invasive estimation of central BP using the Antares algorithm.
In order to be independent of the potential error of peripheral BP measurement, a recalibration of the
brachial BP waveforms was performed by the Antares algorithm internally. The recalibrated mean
arterial pressure and diastolic pressure were used for calibration as an internal preprocessing step.
The Antares algorithm receives a cuff pressure signal in deflation stage as input signal and separates
the pulsatile signal component from the inherent cuff pressure. The single pulse waves are identified.
Weighted, multiple transformation of each pulse wave is based on several analytical steps, which could
be referred to as adaptive transfer function. Grid points are then identified to calculate hemodynamic
parameters such as cBP. The residuum, defined as spread between actual and expected deflating cuff
pressure, is calculated. Arrhythmia and other disturbing artifacts are identified based on the residuum
and the shape of the pulse wave. The integration of Antares in the software of a blood pressure monitor
aims to enable a brachial cuff-based BP monitor to be a type II-device with relatively accurate absolute
central BP values independently from the peripheral BP measurement.
J. Clin. Med. 2019, 8, 1073 5 of 15
Invasive central BP measurement: The invasive central BP measurements and the non-invasive
measurements were performed by following exactly the same protocol with one exception: the invasive
recording time in Greifswald was 20 s, while in Bad Oeynhausen and Bad Berka it was 90 s. All invasive
measurements were performed using fluid-filled catheters. In the majority of measurements (90%),
a 5 French Judkins right or left 3.5 standard diagnostic coronary catheter of 100 cm length was used.
A mix of multiple catheters was used in the remaining 10%. The test to determine frequency response
involves a rapid flush like a rectangular pulse (at least 180 mmHg). After a sudden release, the flush
bag pressure decreases rapidly and forces an overshooting of the baseline. The natural frequency
was calculated from the time between 2nd and 3rd oscillation (one cycle). The damping coefficient
was calculated from the ratio of the amplitudes of those two consecutive oscillations. The routinely
checked natural frequency and damping coefficients of the systems were 21.9 Hz (15–29 Hz) and
0.21 (0.14–0.29), respectively, which surpasses the recommended guidelines [12]. The dataset used to
develop the Antares algorithm is a different dataset from that used in the present validation. The full
dataset of this study is for validation purposes only.
Flushing was performed before each invasive measurement using sodium chloride 0.9%. At the
beginning of the invasive procedure, zeroing was performed precisely, having in mind that inaccuracy
in zeroing will cause severe BP aberration. For calibration of each transducer the zero reference level for
pressure measurement was set at midchest height, which was also used for balancing. Both calibration
and balancing were checked before each measurement was performed. In an undefined number of cases
repeated zeroing was performed according to the examiner’s experience. The correct catheter position
was confirmed by X-ray at the end of the standard procedure, because the invasive measurement was
performed at the end of each heart catheterization. Sample rates at which waveforms were invasively
recorded were 500 Hz in Greifswald, 2000 Hz in Bad Oeynhausen, and 240 Hz in Bad Berka. Waveform
data processing was performed with the use of a Philips Allura Xper FD20 system in Greifswald,
Siemens Sensis Axiom system in Bad Oeynhausen and General Electric MacLab IT system in Bad Berka.
The invasive pressure waves were analyzed semi-automatically over the whole period of the
recording; meaning 20 s in Greifswald, and 90 s in Bad Oeynhausen and Bad Berka, respectively.
To determine the invasive systolic BP, the peak of every recorded pulse wave; for invasive diastolic
BP the lowest signal point; and for invasive mean arterial pressure (MAP) the area under the curve
was taken for the calculation. The pulse waves of the invasive recordings were visually checked and
in that case cleared if they differed greatly from the mean (e.g., artifacts). As an example please see
Figure 2a where, over 90 s, a total of two pulse waves had to be excluded. All other pulse waves
were included in the analysis of central BP, what means that in the end several extrasystoles still were
included. A measurement was considered severe arrhythmia if more than 30% of pulse waves had to
be deleted, and the recording of that patient was withdrawn from the analysis. The values for each
pulse wave were averaged and additionally the standard deviation was calculated. According to the
AAMI protocol, recordings with a SD—within the invasive pressure—of more than 10 mmHg for
systolic BP, 6 mmHg for diastolic BP, and 6 mmHg for MAP were withdrawn from the analysis.
Nitroglycerin was injected at the beginning of the heart catheterization with a time difference of at
least 10 minutes until the invasive and non-invasive recordings of the pulse waves were performed.
No other medication was given closely prior to the recordings of the pulse waves.
Figures 1–3 show original non-invasive and invasive recordings of a 65-year-old lady to illustrate
how data were processed and analyzed.
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Figure 3. Distribution of the central blood pressures (BP) of the same 65-year-old lady, extracted from
the invasive recordings with (from left to right) central diastolic BP, central mean arterial pressure,
and central systolic BP.
All patient data and measurement results were stored in a database (Excel 2016, Microsoft Corp.,
Redmond, WA, USA). Statistical analysis was performed using IBM SPSS 22 software (IBM Corp.,
Armonk, NY, USA). Data are presented as means ±standard deviation. The Pearson correlation
coefficient was used to assess the strength of linear correlation between invasive and estimated central
BP. Furthermore, the regression equation y = ax + b was used to create a trend line in the scatter plots
to evaluate the relationship between the pressures. The agreements between invasive and estimated
central BP were compared using Bland–Altman analysis. Statistical significance was declared at the
two-side p < 0.05 level.
3. Results
The coefficient of determination of estimated central systolic BP to invasively measured central
systolic BP was r2 = 0.86. The mean difference was 0.71 mmHg and SD was 5.95 mmHg. For diastolic
BP, the correlation was r2 = 0.71, mean difference 2.96 mmHg and SD 5.21 mmHg. For MAP, correlation
was r2 = 0.84, mean difference 0.19 mmHg and SD 3.78 mmHg. The corresponding scatter plots and
Bland–Altman plots revealed good limits of agreement. The trend lines illustrate no significant over-or
underestimations for systolic BP, MAP or diastolic BP. Figures 4–9 show the results in detail.
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blood pressure SD were excluded from the analysis. Table 3 shows the distribution of measurement
errors of the Antares algorithm within the ranges of <5 mmHg, <10 mmHg and <15 mmHg.
Table 3. Distribution of measurement errors of the Antares algorithm within the ranges of <5 mmHg,
<10 mmHg and <15 mmHg. According all recommended standards, including Association for the
Advancement of Medical Instrumentation (AAMI), ARTERY, European Society of Hypertension (ESH)
and British Hypertension Society (BHS), Antares surpasses grade-A-criteria for central systolic blood
pressure (SBP), central mean arterial pressure (MAP), and central diastolic blood pressure (DBP).
Error <5 mmHg <10 mmHg <15 mmHg
Estimated central SBP 89 61.4% 123 84.8% 144 99.3%
Estimated central MAP 118 81.4% 143 98.6% 145 100.0%
Estimated central DBP 89 61.4% 127 87.6% 141 97.2%
4. Discussion
The study confirmed that the Antares algorithm turns the oscillometric custo screen 400 blood
pressure monitor into a type II-device for non-invasive estimation of true central BP fulfilling entirely
the 2017 ARTERY validation protocol (Table 4) as well as the 2013 ANSI/AAMI/ISO 81060-2 and the
2018 AAMI/ESH/ISO validation protocol including the criteria for high-accuracy devices.
This validation study, which is comparing the invasively measured central BP with the non-invasive
estimation using a regular oscillometric BP device, shows a level of agreement that faces the highest
requirements as defined as the mean value of differences within five mmHg and standard deviation of
less than 8 mmHg [7]. We did not show the results of agreement with the invasively measured cBP
values when the non-invasive pulse waves were calibrated by the invasively measured MAP and DBP.
The reason is that we strongly believe in clinical demands. The widespread use of invasive data for
calibration of non-invasive oscillometric devices may lead to over-expectation of the performance of
any oscillometric solution. However, clinically it would not make any sense to calibrate invasively
a non-invasive oscillometric measurement for estimation of central BP. On the other hand, the good
agreement with the invasive BP is achievable only if the peripheral BP is recalibrated to avoid the
potential error of peripheral BP measurement as described earlier [8,12]. For recalibration, the area
under the curve of every oscillometrically recorded pulse wave is used by Antares. The results of
the recalibration are not displayed because they are for preprocessing purposes only. In other words:
the Antares algorithm must have access to the oscillometric raw data in the deflation of the upper
arm cuff to perform pulse wave analysis (PWA) with recalculation of MAP and diastolic BP as well as
performing PWA for calculation of the corresponding central BP. Doing this, for systolic BP a mean
difference of 0.71 mmHg is reached in comparison to the simultaneous invasive measurement.
According to the 2013 ANSI/AAMI/ISO 81060-2 protocol, the ranges of the invasively measured
BP as reference blood pressure for comparison of the estimated central BP were for central systolic
BP 10 mmHg and for diastolic BP 6 mmHg. In this way, a hemodynamic stability can be assumed.
The residual pressure fluctuations may reflect a physiologic pressure range. Patients with arrhythmia
in more than 30% of the recorded pulse waves were excluded. Again, this procedure is undertaken in
order to achieve acceptable hemodynamic stability. To set the maximum for arrhythmic pulse waves to
30% of all invasively recorded pulse waves means that a relatively high number of patients with a
certain degree of arrhythmia were still included in the calculation. Nevertheless, the level of agreement
with a mean difference for estimated systolic BP of 0.71 mmHg and SD of 5.95 mmHg could be reached.
Moreover, the data are pooled from three different study sites that could bear another potential error.
Still, the measured BP is within the best acceptable range. “Best acceptable range” means for the 2017
ARTERY standard that the device tested passes the validation criteria with mean difference < 5 mmHg,
SD < 8 mmHg without fail criteria, for the 2017 AAMI protocol that mean difference is below 5 mmHg
with SD below 8 mmHg, for the 2018 AAMI/ESH/ISO protocol if an estimated probability of a tolerable
error (≤ 10 mmHg) is at least 85%, and for the British Hypertension Society (BHS) if it passes grade A
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criteria. Consequently, for all named protocols, the results of the Antares algorithm to estimate cBP are
within the best acceptable range. Thus, when implemented into the device, it may be concluded that
the Antares algorithm is robust and could be used in the real world in order to non-invasively estimate
the central BP.
Table 4. Summary of central blood pressure device validation protocol components and requirements
of the 2017 ARTERYs validation consensus statement applied to the present validation study.
Protocol Section Protocol Item ProtocolRequirement
Protocol Undertaken
with Comment
Study setting Isolated room without disturbinginfluences Should Yes
Non-invasive central
blood pressure device
measurement standards
List manufacturer, model, software
version, operating principles, signal
processing step/s, calibration
processes
Must Yes
Time for blood pressure measures;
time points of brachial and central
blood pressure; cuff deflation speed
Should Yes
Define and use appropriate cuff size Must Yes
Dimensions of inflatable bladder for
all cuff sizes available; process to
determine cuff size
Should Yes
Process familiarization with
equipment Should Yes
Separate validation studies for
additional or optional features or
functions
Must Yes, here focus on centralblood pressures
Process of quality control; process
used to delineate acceptable quality;
number of unacceptable readings;
reason/s for exclusion
Must Yes
Invasive (intra-arterial)
central blood pressure
reference standard
Micromanometer-tipped catheter
used if minor inflection points to be
identified
Should
Not applicable because
no waveform features are
topic of this validation
Full description of catheter;
frequency response and handling
procedures
Must Yes
Performance comparison of
fluid-filled catheter with
micromanometer-tipped catheter
May No
Data acquisition at rest Period of undisturbed rest;medications used Should Yes
No talking. Free from acute
hemodynamic interventions Must Yes
Test device compared with reference
over time-period matching the test
device deflation cycle; recorded
under stable conditions
Must Yes
Complete description of protocol;
time interval between test device
and reference measures
Must Yes
Data acquisition at blood
pressure intervention
Hemodynamic change from resting
state May No
Description of the intervention
procedure Must
Not applicable because
no intervention done
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Limitations
All invasive measurements were performed using fluid-filled catheters. The biggest advantage
of using fluid-filled catheters is that they can be easily integrated into everyday clinical practice.
This allows achieving a sufficient number of patients included in the invasive measurement,
is cost-effective and, furthermore, enhances the probability to show results that can be verified
by other working groups easily. One disadvantage compared to micromanometer-tipped catheters is
that they are susceptible to false pressures due to damping and altered frequency response. For the
given fluid-filled catheters, the coefficient of damping and frequency response were within a generally
accepted range [13]. Another advantage of high-frequency, micromanometer-tipped catheters with
high-frequency acquisition systems is that they can be used to determine specific waveform features.
Thus, the present validation focuses on the invasive validation of cBP and is not a validation of any
waveform feature.
The invasive and non-invasive measurements were performed at the end of each cardiac
catheter simultaneously. There was no lag of time between those measurements. However, 100%
synchronization via R-peak was not done. To the best of our knowledge this should be acceptable
because following the 2013 AAMI protocol, physiologic pressure fluctuations already were taken into
account and should be covered by the length of the invasive measurements (20 s in Greifswald, 90 s in
Bad Oeynhausen and Bad Berka, respectively). It cannot be completely ruled out that this procedure
introduces a systematic error when comparing periods of different length. From a clinical point of view
it may be advantageous to compare the estimated cBP with the invasive measurement procedure that
comes as close as possible to the “true” central pressure. To average the cBP of an invasive recording of
90 s might be closer to the “true” cBP than a shorter period of 20 or 30 s. Therefore we followed the 2013
AAMI protocol and used the concept of hemodynamic stability of an entire invasive measurement,
which timewise envelops the oscillometric measurement.
Though the development of the recalculated “new” brachial BP was done based on invasive
comparisons (simultaneous invasive and non-invasive brachial BP measurements on both arms),
the method of recalculation of the brachial BP is not invasively validated itself, but considered
preprocessing only. Accordingly, the recalculated values are not displayed as discussed above. Thus,
it has to be concluded that an exact estimation of aorta-to-brachial systolic BP amplification cannot be
gauged using the Antares algorithm. This is partly because it is the nature of a type II-device instead
of providing a type I-device. The decision to have a type II-device was reinforced by findings that
type II-devices have proved better risk stratification for hypertension-related end organ damage and
outcome then type I-devices [14–18].
The AAMI protocols as well the ARTERY protocol suggest that an indicative range for invasive
central systolic BP may be below/equal 100 mmHg in 5% of the readings and above/equal 160 mmHg
in 5% of the readings, and invasive central diastolic BP may be below/equal 60 mmHg in 5% of the
readings and above/equal 85 mmHg in 5% of the readings. In the validation protocols this BP criterion
is categorized as “may”, which means that this criterion provides further guidance and is not a “must”
or “should” recommendation. Although we have measured invasively in total 191 patients and could
use data of 145 patients for the analysis, we could include in the extreme BP ranges only three patients
for central SBP below/equal 100 mmHg and 17 patients for central DBP of above/equal 85 mmHg.
The corresponding Bland–Altman plots have a good level of accordance without any significant trend.
However, it has to be stated that further invasive comparisons have to show if within these extreme BP
ranges Antares works to a similarly robust degree as shown for the other ranges.
5. Conclusions
With the integrated Antares algorithm, the oscillometric blood pressure device studied here proofs
to serve as a type II-device for estimation of true central BP. Antares fulfills entirely the 2017 ARTERY
validation protocol as well as the 2013 ANSI/AAMI/ISO and the 2018 AAMI/ESH/ISO validation
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protocols including the criteria for high accuracy devices for estimation of central BP. Whether Antares
can be integrated reliably with similar robust results in other oscillometric devices has yet to be proven.
The integration of a feature for measuring central blood pressure in commercially available blood
pressure monitors could make it possible to measure these parameters in every practice in the future.
The existing knowledge about the significance of central blood pressure could then finally be applied
more widely in clinical practice.
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